English Version
OK
Logo retour accueil
 

16.12.2014

Collaboration with PICCOLO study investigators

IntegraGen has announced a collaboration with the team of investigators from the PICCOLO study to further validate the role of biomarker hsa-miR-31-3p in metastatic colorectal cancer (mCRC).


Link to press release 

02.12.2014

IntegraGen licences liver cancer molecular signatures

IntegraGen has announced that it has entered into an agreement providing the company with the worldwide licensing rights for two hepatocellular carcinoma molecular signatures which have potential clinical utility for monitoring patients with liver cancer.


Click here to view press release. 

07.10.2014

IntegraGen reports 1st half results for 2014

IntegraGen released financial results for the half year ending on June 30, 2014.

Click here to view press release.

03.10.2014

IntegraGen presents data on oncology biomarker at ESMO meeting

IntegraGen presented data at ESMO 2014 confirming that its microRNA biomarker predicts survival in patients with metastatic colorectal cancer.

Expression of the company's proprietary hsa-miR-31-3p bimoarker was shown to predict impact of anti-EGFR therapy on progression free survival in all-RAS wild-type patients with metastatic colorectal cancer. The data presented was based on a post-hoc analysis of patients enrolled in the New EPOC phase III trial who were randomized to receive chemotherapy alone or chemotherapy plus cetuximab before and after resection of colorectal liver metastasis. These results confirm those previously presented at ASCO 2014 this past June in Chicago.

Click here to view press release 

Link to poster with results from research  

03.09.2014

Collaboration with French Intergroup of Thoracic Oncology (IFCT)

IntegraGen is collaborating with the French Intergroup of Thoracic Oncology (IFCT) to explore the role of its proprietary miR-31-3p biomarker in advanced stage non-small cell lung cancer (NSCLC).


The study aims to identify whether the expression of the microRNA miR-31-3p is correlated with outcomes associated with the use of epidermal growth factor receptor (EGFR) targeted therapies for lepidic adenocarcinomas of the lung. If the results from this initial study are positive, the collaboration could be expanded to additional IFCT studies with miR-31-3p exploring its association with EGFR-targeted therapy-related outcomes in other types of lung cancer.

Click here to view press release


23.06.2014

Interpretation of Clinical Exome (ICE) Project

Integragen, Gustave Roussy, INSERM and Sogeti High Tech announce the launch of the Interpretation of Clinical Exome (ICE) Project.

Collaborative project will lead to the development of an advanced scientific software program that will support data interpretation of genome sequencing performed for cancer patients. The objective of the ICE Project is to optimize the diagnosis of cancer patients and to develop a data driven approach for identifying targeted treatment options for these patients.


Link to press release. 

02.06.2014

IntegraGen presents data at 2014 ASCO Meeting

IntegraGen announced today that it presented data during the American Society of Clinical Oncology’s 2014 Annual Meeting which demonstrates that the oncology biomarker miR-31-3p is predictive of cetuximab effects in wild-type (WT) KRAS metastatic colorectal cancer (mCRC) patients.


The data presented was based on a post-hoc analysis of patients enrolled in the New EPOC phase III trial who were randomized to receive chemotherapy alone or chemotherapy plus cetuximab before and after resection of colorectal liver metastasis.

Link to press release

Link to poster detailing results from study presented at ASCO 2014

19.05.2014

IntegraGen presents data at 2014 IMFAR meeting

IntegraGen presented data on the newest version of the ARISk Test during the 2014 International Meeting for Autism Research (IMFAR) held in Atlanta, Georgia.

The ARISk2 Test permits the ability to predict the risk of autism spectrum disorder (ASD) in children with signs of developmental delay or autism.

The study, based on an analysis of approximately 3,000 individuals diagnosed with ASD and 3,000 controls, identifed over 1,700 common genetic variants which were shown to be associated with the risk of autism. 

 Link to press release

15.05.2014

IntegraGen announces publication on oncology biomarker

The results of a study with IntegraGen's proprietary oncology biomarker, miR-31-3p, have been published in Clinical Cancer Research.

The paper provides data on the ability this microRNA to predict progression-free survival in metastatic colorectal cancer patients treated with anti-EGFR therapy.

Link to press release

Link to publication 

 
25.04.2014

GenomeWeb reports on IntegraGen and Gustave Roussy partnership

GenomeWeb has published a story on IntegraGen's partnership with Gustave Roussy to support clinical cancer trials with exome and RNA sequencing (subscription required).

Link to story

23.04.2014

New Paper Published in "Frontiers in Pediatrics"

A new paper based on an IntegraGen-sponsored survey of parents of children with autism spectrum disorder has been published in "Frontiers in Pediatrics".

The paper, entilted "Are there cultural differences in parental interest in early diagnosis and genetic risk assessment for autism specrtrum disorders" reconfirms the significant delay children experience in receiving an autism diagnosis.

Click here to view paper. 

11.04.2014

IntegraGen announces 2013 financial results

Integragen today announced its financial results for the year ended 31 December 2013. 

The financial statements were reviewed by the Board of Directors held 10 April 2014.

The financial statements were reviewed by the Company's Board of Directors during a meeting held on April 10, 2014.

Click here to view press release 

03.04.2014

Collaborative agreement with Pfizer

IntegraGen announces Collaborative Agreement with Pfizer to evaluate IntegraGen's proprietary Hepatocellular Carcinoma Molecular signature.

Collaborative agreement with Pfizer
01.04.2014

IntegraGen shares eligible for PEA PME

 IntegraGen shares (ALINT- FR0010908723 ) are eligible for PEA PME



 

24.03.2014

IntegraGen and Gustave Roussy Announce High-Throughput Sequencing Unit

IntegraGen and Gustave Roussy announce the set-up of a High-Throughput Oncology Clinical Sequencing Unit.

Unit will be operated by IntegraGen within Gustave Roussy and will identify somatic genetic alterations within the whole exome of a patient’s tumor  permitting personalized cancer treatments.

Link to press release

21.02.2014

IntegraGen publishes new data on genetic risk of autism

Results of a new study were published in Frontiers in Genetics which support the association of common genetic variants in the development of autism.

The study, done in partnership with external researchers in the field of autism, combined functional genomics and statistical methods to develop a gender specific genetic score for the identification of autism risk.

The research was based on results obtained from genome-wide association studies utilizing data from the Autism Genetic Resource Exchange (AGRE) and a separate independent replication sample. The study included 2,000 individuals diagnosed with ASD, as well as 600 unaffected siblings. The results of the study support the role of common variants, also known as single-nucleotide polymorphisms (SNPs), in multiplex autism families.

Press release: http://goo.gl/hixLZg 

Link to publication: http://goo.gl/5IECjD

10.02.2014

IntegraGen donates to autism charity following 20 km of Paris race

On October 13, 2014, runners from the IntegraGen team completed the Paris 20 km race. Despite cold weather conditions, the team distinguished itself with good times.

Based on times achieved by each runner, a donation of €1,079 was made to the Roussillon Sesame Autism Association, an organiztion for parents of children with autism located in Perpignan, France.

http://www.sesameautisme66.com/  

 

10.02.2014

IntegraGen to present at Autism Investment Conference

IntegraGen will be presenting during Autism Speaks' upcoming 2014 Autism Investment Conference being held on March 4th and 5th in San Francisco, California.

The company will provide an overview of the newest version of it's ARISk Autism Risk Assessment Test which is now available for pediatricians to utilize for children who have signs of developmental day or autism spectrum disorder.

2014 Autism Investment Conference

Meeting website: http://www.autismspeaks.org/aic

IntegraGen will present during the session on "Diagnostics and Risk Assessment" scheduled for Tuesday, March 4th from 10:30 a.m. to 11:15 a.m. Pacific Time. 

Potential investors interested in meeting with representatives from IntegraGen during the Autism Investment Conference can contact the company in advance by email at contact@integragen.com to arrange a meeting. 

21.01.2014

2013 Annual Results

IntegraGen announced today the company's sales results for the year ending December 31, 2013


CA 2013: € 5.45 million
Profit up 15% compared to previous year.

Click here to view press release. 

14.01.2014

Collaboration with New EPOC Study

IntegraGen has announced a collaboration with the team of investigators from the New EPOC study to validate the role of biomarker hsa-miR-31-3p in metastatic colorectal cancer (mCRC).

Click here to view press release.

28.10.2013

IntegraGen presents study data at AACAP meeting

IntegraGen presented data at the 60th Annual meeting of the American Academy of Child & Adolescent Psychiatry in Orlando, Florida reporting on the identification of over 1,500 genetic variants associated with autism.

The results of this study will be used to develop a new, broader version of the ARISk Test which will be designed to identify the risk of autism in children with signs of developmental delay or autism. 

Click here
 to view press release.

23.10.2013

IntegraGen reports 1st half results for 2013

IntegraGen released financial results for the half year ending on June 30, 2013. Revenue grew by 18% compared to the first half of 2012.

Click here to view press release

14.10.2013

IntegraGen obtains exclusive license for microRNA for mCRC

IntegraGen has obtained exclusive licensing rights for the oncology biomarker hsa-miR-31-3p, a microRNA which predicts progression free survival in patients with metastatic colorectal cancer treated with anti-EGFR therapy.

Click here to view press release

04.06.2013

IntegraGen presents research at 2013 ASCO meeting

IntegraGen presented results on the company's latest research related to use of its proprietary microRNA biomarker to predict response to anti-EGFR therapy in KRAS wild-type metastatic colorectal cancer patients.

1. "Hsa-miR-31-3p expression in FFPE tumor samples as a predictor of anti-EGFR response in patients with metastric colorectal cancer"  

2. "Hsa-miR-31-3p effects on gene expression in colorectal cell lines and patients"  

22.02.2013

Lab21 and IntegraGen : agreement for a CE marked assay

Lab21 and IntegraGen partner to develop new colorectal cancer diagnostic

Cambridge,UK –22nd February 2013 - Lab21 Limited, the global specialist in personalised medicine and clinical diagnostics, has entered into an agreement with IntegraGen, to develop a microRNA assay for colorectal cancer designed to further improve patient outcomes.

see more >

Press Release Lab21 Ltd.

20.12.2012

Formation of Autism Community Advisory Panel

IntegraGen announced today the formation of a Community Advisory Panel to provide the company with insight and feedback on planned educational materials and informational programs directed towards the autism community.

Link to press release  

Link to list of Autism Community Advisory Panel members

28.11.2012

Autism Parental Survey Published in Clinical Pediatrics

A new publication entitled "Parental Interest in a Genetic Risk Assessment Test for Autism Spectrum Disorders," has been published online in the journal of Clinical Pediatrics.

Link to publication

17.10.2012

Autism center in U.S. conducting study with ARISk Test

The Knights of Columbus Developmental Center at SSM Cardinal Glennon Children's Medical Center in St. Louis, Missouri is conducting a study with the ARISk Test.  

Link to more information about study


12.07.2012

IntegraGen announces additional financing

IntegraGen announced that the company has received €2 millions in financing from funds managed by A Plus Finance. The funds will be used to support the company's efforts with biomarker development for colorectal and liver cancer and develop/commercialization efforts in the field of autism molecular diagnostics.  

Link to press release


17.05.2012

IntegraGen presents autism research at IMFAR

IntegraGen announced today the presentation of scientific data which demonstrates the role of common genetic variants towards the identification of risk of autism in siblings of children diagnosed with autism spectrum disorders during the 2012 International Meeting for Autism Research. 

Link to press release

17.04.2012

Appointment of Michael Dresner

IntegraGen, Inc. Names Michael Dresner National Sales Director

Cambridge, MA (April 17, 2012) - IntegraGen, Inc., a biotechnology company dedicated to molecular biomarker discovery, has named Michael E. Dresner National Sales Director. He will be responsible for IntegraGen's sales efforts in the U.S. associated with the ARISk™ Autism Risk Assessment Test. 


Link to press release 

06.03.2012

Huge growth in Genomic Services in 2011

March 6th, : IntegraGen announces today revenues for the year ending December 31, 2011. The company also announced the signing of two pharmacogenomic contracts and the launch of a new personalized sequencing service, the first offering of this type  in France

IntegraGen becomes the first French Services Lab equipped with an Illumina MiSeq.

Huge growth in Genomic Services in 2011
Disclaimers - Mentions légales - Crédits